Jasleen Kukreja

Jasleen Kukreja

Auto-generated profile, based on publicly available information

Jasleen Kukreja

Department of Surgery, University of California, San Francisco, San Francisco, CA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
DCDaniel R. Calabrese
Daniel R. Calabrese
EAEmily Aminian
Emily Aminian
BMBenat Mallavia
Benat Mallavia
FLFengchun Liu
Fengchun Liu
SCSimon J. Cleary
Simon J. Cleary
JGJohn Greenland
John Greenland
Pulmonary ischemia-reperfusion injury (IRI) is a clinical syndrome of acute lung injury that occurs after lung transplantation or remote organ ischemia. IRI causes early mortality and has no effective therapies. While NK cells are innate lymphocytes capable of recognizing injured cells, their roles in acute lung injury are incompletely understood. Here, we demonstrated that NK cells were increased in frequency and cytotoxicity in 2 different IRI mouse models. We showed that NK cells trafficked to the lung tissue from peripheral reservoirs and were more mature within lung tissue. Acute lung ischemia-reperfusion injury was blunted in a NK cell–deficient mouse strain but restored with adoptive transfer of NK cells. Mechanistically, NK cell NKG2D receptor ligands were induced on lung endothelial and epithelial cells following IRI, and antibody-mediated NK cell depletion or NKG2D stress receptor blockade abrogated acute lung injury. In human lung tissue, NK cells were increased at sites of ischemia-reperfusion injury and activated NK cells were increased in prospectively collected human bronchoalveolar lavage in subjects with severe IRI. These data support a causal role for recipient peripheral NK cells in pulmonary IRI via NK cell NKG2D receptor ligation. Therapies targeting NK cells may hold promise in acute lung injury.

31 August 2022 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
ECEdward Cantu
Edward Cantu
JDJoshua M. Diamond
Joshua M. Diamond
MCMarisa Cevasco
Marisa Cevasco
YSYoshi Suzuki
Yoshi Suzuki
MCMaria Crespo
Maria Crespo
JCJason D. Christie
Jason D. Christie

2 November 2020 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
SCSimon J. Cleary
Simon J. Cleary
NKNicholas Kwaan
Nicholas Kwaan
JTJennifer J. Tian
Jennifer J. Tian
DCDaniel R. Calabrese
Daniel R. Calabrese
BMBeñat Mallavia
Beñat Mallavia
MLMark R. Looney
Mark R. Looney
Antibodies targeting human leukocyte antigen (HLA)/major histocompatibility complex (MHC) proteins limit successful transplantation and transfusion, and their presence in blood products can cause lethal transfusion-related acute lung injury (TRALI). It is unclear which cell types are bound by these anti-leukocyte antibodies to initiate an immunologic cascade resulting in lung injury. We therefore conditionally removed MHC class I (MHC I) from likely cellular targets in antibody-mediated lung injury. Only the removal of endothelial MHC I reduced lung injury and mortality, related mechanistically to absent endothelial complement fixation and lung platelet retention. Restoration of endothelial MHC I rendered MHC I–deficient mice susceptible to lung injury. Neutrophil responses, including neutrophil extracellular trap (NET) release, were intact in endothelial MHC I–deficient mice, whereas complement depletion reduced both lung injury and NETs. Human pulmonary endothelial cells showed high HLA class I expression, and posttransfusion complement activation was increased in clinical TRALI. These results indicate that the critical source of antigen for anti-leukocyte antibodies is in fact the endothelium, which reframes our understanding of TRALI as a rapid-onset vasculitis. Inhibition of complement activation may have multiple beneficial effects of reducing endothelial injury, platelet retention, and NET release in conditions where antibodies trigger these pathogenic responses.

11 February 2014 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
JGJohn Greenland
John Greenland
NJN. P. Jewell
N. P. Jewell
MGM. Gottschall
M. Gottschall
NTN. N. Trivedi
N. N. Trivedi
JKJ. Kukreja
J. Kukreja
GCG. H. Caughey
G. H. Caughey
Supplementary methods to identify acute rejection and to distinguish rejection from infection may improve clinical outcomes for lung allograft recipients. We hypothesized that distinct bronchoalveolar lavage (BAL) cell profiles are associated with rejection and infection. We retrospectively compared 2939 BAL cell counts and immunophenotypes against concomitantly obtained transbronchial biopsies and microbiologic studies. We randomly assigned 317 subjects to a derivation or validation cohort. BAL samples were classified into four groups: infection, rejection grade ≥A1, both or neither. We employed generalized estimating equation and survival modeling to identify clinical predictors of rejection and infection. We found that CD25+ and natural killer cell percentages identified a twofold increased odds of rejection compared to either the infection or the neither infection nor rejection groups. Also, monocytes, lymphocytes and eosinophil percentages were independently associated with rejection. A four‐predictor scoring system had high negative predictive value (96–98%) for grade ≥A2 rejection, predicted future rejection in the validation cohort and predicted increased risk of bronchiolitis obliterans syndrome in otherwise benign samples. In conclusion, BAL cell immunophenotyping discriminates between infection and acute rejection and predicts future outcomes in lung transplant recipients. Although it cannot replace histopathology, immunophenotyping may be a clinically useful adjunct.

12 January 2023 in American Journal of Transplantation
Verified
Journal Article
Open access
DSDeirdre Sawinski
Deirdre Sawinski
JLJennifer C. Lai
Jennifer C. Lai
SPSean Pinney
Sean Pinney
AGAlice L. Gray
Alice L. Gray
AJAnnette M Jackson
Annette M Jackson
EPElizabeth Pomfret
Elizabeth Pomfret
Solid organ transplantation provides the best treatment for end-stage organ failure, but significant sex-based disparities in transplant access exist. On June 25, 2021, a virtual multidisciplinary conference was convened to address sex-based disparities in transplantation. Common themes contributing to sex-based disparities were noted across kidney, liver, heart, and lung transplantation, specifically the existence of barriers to referral and wait listing for women, the pitfalls of using serum creatinine, the issue of donor/recipient size mismatch, approaches to frailty and a higher prevalence of allosensitization among women. In addition, actionable solutions to improve access to transplantation were identified, including alterations to the current allocation system, surgical interventions on donor organs, and the incorporation of objective frailty metrics into the evaluation process. Key knowledge gaps and high-priority areas for future investigation were also discussed.

1 August 2017 in Annals of the American Thoracic Society
Verified
Journal Article
Closed access
MBMatthew R. Baldwin
Matthew R. Baldwin
JSJonathan P. Singer
Jonathan P. Singer
DHDebbie Huang
Debbie Huang
JSJessica Sell
Jessica Sell
WGWendy C. Gonzalez
Wendy C. Gonzalez
DLDavid J. Lederer
David J. Lederer
Rationale: The frail phenotype has gained popularity as a clinically relevant measure in adults with advanced lung disease and in critical illness survivors. Because respiratory disease and chronic illness can greatly limit physical activity, the measurement of participation in traditional leisure time activities as a frailty component may lead to substantial misclassification of frailty in pulmonary and critical care patients. Objectives: To test and validate substituting the Duke Activity Status Index (DASI), a simple 12-item questionnaire, for the Minnesota Leisure Time Physical Activity (MLTA) questionnaire, a detailed questionnaire covering 18 leisure time activities, as the measure of low activity in the Fried frailty phenotype (FFP) instrument. Methods: In separate multicenter prospective cohort studies of adults with advanced lung disease who were candidates for lung transplant and older survivors of acute respiratory failure, we assessed the FFP using either the MLTA or the DASI. For both the DASI and MLTA, we evaluated content validity by testing floor effects and construct validity through comparisons with conceptually related factors. We tested the predictive validity of substituting the DASI for the MLTA in the FFP assessment using Cox models to estimate associations between the FFP and delisting/death before transplant in those with advanced lung disease and 6-month mortality in older intensive care unit (ICU) survivors. Results: Among 618 adults with advanced lung disease and 130 older ICU survivors, the MLTA had a substantially greater floor effect than the DASI (42% vs. 1%, and 49% vs. 12%, respectively). The DASI correlated more strongly with strength and function measures than did the MLTA in both cohorts. In models adjusting for age, sex, comorbidities, and illness severity, substitution of the DASI for the MLTA led to stronger associations of the FFP with delisting/death in lung transplant candidates (FFP-MLTA hazard ratio [HR], 1.42; 95% confidence interval [CI], 0.55–3.65; FFP-DASI HR, 2.99; 95% CI, 1.03–8.65) and with mortality in older ICU survivors (FFP-MLTA HR, 2.68; 95% CI, 0.62–11.6; FFP-DASI HR, 5.71; 95% CI, 1.34–24.3). Conclusions: The DASI improves the construct and predictive validity of frailty assessment in adults with advanced lung disease or recent critical illness. This simple questionnaire should replace the more complex MLTA in assessing the frailty phenotype in these populations.